

EDITORIAL ADVISORY PANEL

- N. H. Andersen (Aarhus)
C. Austin (Manchester)
D. Bhatnagar (Oldham)
I. Biaggioni (Nashville, TN)
C. E. Brightling (Leicester)
A. Burt (Newcastle upon Tyne)
D. Callen (Adelaide, S. Aus.)
J. D. Cameron (Dandenong, Vic.)
V. Cameron (Christchurch, NZ)
A. Carter (Leeds)
J. P. F. Chin-Dusting (Melbourne)
P. Chowienczyk (London)
J. de Graaf (Nijmegen)
S. Duthie (Aberdeen)
K. Evans (Stafford)
A. Ferrante (North Adelaide)
C. Ferri (L'Aquila)
J. Floras (Toronto)
G. A. Ford (Newcastle upon Tyne)
D. Freeman (Glasgow)
L.-M. Gan (Goteburg)
B. Garner (Sydney)
G. J. Gibson (Newcastle upon Tyne)
S. Gough (Birmingham)
A. Graham (Glasgow)
G. Grassi (Milan)
D. J. Green (Nedlands, WA)
F. R. Green (Oxford)
M. Grimm (Kogarah, NSW)
N. Haites (Aberdeen)
J. D. Imig (Augusta, GA)
E. W. Inscho (Augusta, GA)
B. Jilma (Vienna)
J. T. Kielstein (Stanford, CA)
L. Kritharides (Sydney)
D. S. Kumararatne (Cambridge)
T. Kuo (Hualien)
P. Little (Melbourne)
D. Lobo (Nottingham)
R. A. Malik (Manchester)
P. G. McTernan (Coventry)
J. Mullins (Edinburgh)
S. Nagueh (Houston, TX)
L. Ng (Leicester)
T. Nyström (Stockholm)
M. J. O'Leary (Sydney)
T. Omland (Oslo)
G. Parati (Milan)
S. Phillips (Hamilton)
M. Rademaker (Christchurch, NZ)
J. Rhodes (Liverpool)
R. Rush (Adelaide)
C. Schalkwijk (Maastricht)
M. Schillinger (Vienna)
F. C. Schmalstieg, Jr (Galveston)
T. Shimosawa (Tokyo)
C. C. Shoulders (London)
S. S. Smyth (Chapel Hill, NC)
I. Squire (Leicester)
J. Staessen (Leuven)
H. Stauss (Berlin)
I. Striz (Prague)
D.-F. Su (Shanghai)
S. R. Thomas (Sydney)
N. C. Thomson (Glasgow)
V. Thongboonkerd (Bangkok)
H. Tomiyama (Tokyo)
M. van der Giet (Berlin)
J. J. Van Lieshout (Amsterdam)
M. Verma (Bethesda)
S. Watts (East Lansing)
M. Weiss (Munich)
J. Wernerman (Huddinge)
M. J. White (Birmingham)
J. Wilson (Bankstown, NSW)
R. Woodman (Perth, WA)
S. Ye (London)
C.-M. Yu (Hong Kong)
C. Zhang (Newark)
J. Zicha (Prague)

**Published by Portland Press on behalf of the
Biochemical Society**

© **The Biochemical Society 2007**

ISSN 0143-5221

Printed in Great Britain by the Charlesworth Group, Wakefield

A U T H O R I N D E X

- A**akhus, S. 287–296
 Alp, N. J. 47–63
 Angus, P. W. 109–118
 Anract, P. 149–155
 Ascensão, A. 459–466
 Aubert, A. E. 329–337
- B**aessler, A. 213–218
 Bailey, S. D. 365–367
 Bakker, S. J. L. 33–40
 Baldoni, M. 103–108
 Barden, A. E. 409–416
 Beaudeau, J.-L. 149–155
 Beckers, F. 329–337
 Betteridge, D. J. 427–434
 Blanchard, B. E. 251–258
 Boehm, E. 205–212
 Bonnefont-Rousselot, D. 149–155
 Borderie, D. 149–155
 Bosch, R. J. 319–327
 Bosselaar, M. 33–40
 Brecker, S. J. D. 25–32
 Brouwers, M. C. G. J. 375–381
 Brown, N. J. 267–278
 Bruijnzeels, M. 369–374
- C**accianiga, G. L. 103–108
 Calabrò, R. 259–266
 Cannizzaro, S. 443–448
 Casati, M. 103–108
 Caso, P. 259–266
 Castaldi, B. 259–266
 Castoldi, G. 103–108
 Chae, J. S. 349–356
 Challet, E. 417–425
 Chen, H. I. 279–285
 Christie, J. J. 233–241
 Clark, J. 297–311
 Clemente, C. F. M. Z. 195–204
 Coll, A. P. 171–182
 Collinson, P. O. 25–32
 Cooper, J. A. 435–441, 467–472
- Cooper, M. B. 427–434
 Curi, R. 65–77
 Cury-Boaventura, M. F. 65–77
- D**ajnowiec, D. 15–23
 D'Andrea, A. 259–266
 Danilowicz-Szymanowicz, L. 131–140
 De Bari, C. 339–348
 de Bruin, T. W. A. 375–381
 de Jongh, R. T. 83–91
 Delemarre-van de Waal, H. A. 83–91
 Dell'Accio, F. 339–348
 Der Sarkissian, S. 357–364
 Di Pasquale, P. 443–448
 di Salvo, G. 259–266
 Drake, A. J. 219–232
 Dunstan, J. A. 409–416
- E**dvardsen, T. 287–296, 394–395
 Ekindjian, O. G. 149–155
 Engert, J. C. 365–367
 Erdmann, J. 213–218
 Esbrit, P. 319–327
- F**asullo, S. 443–448
 Ferrarese, C. 103–108
 Ferreira, R. 459–466
 Fischer, M. 213–218
 Franchini, K. G. 195–204
 Fredriksson, K. 313–318
- G**able, D. R. 467–472
 Gala, S. 259–266
 Galimberti, S. 103–108
 Ganci, F. 443–448
 Gaze, D. C. 25–32
 Giambanco, F. 443–448
 Giovanna Russo, M. 259–266
 Gisolf, J. 329–337
 Gjesdal, O. 287–296, 394–395
- González-Armengol, J. J. 319–327
 González del Castillo, J. M. 319–327
 Gorjão, R. 65–77
 Go-Schön, I. K. 401–407
 Gourmelen, S. 417–425
 Gregson, H. 25–32
 Grobe, J. L. 357–364
 Guardiola-Lemaitre, B. 417–425
 Guldstrand, M. C. 397–399
- H**amilton, P. K. 157–170
 Hammarqvist, F. 313–318
 Hatanaka, E. 65–77
 Hébert, R. L. 297–311
 Heine, R. J. 33–40
 Helle-Valle, T. 287–296
 Hengstenberg, C. 213–218
 Hengstenberg, W. 213–218
 Holmer, S. 213–218
 Holubarsch, C. J. F. 205–212
 Hopp, E. 287–296
 Hubbart, C. 435–441
 Hughes, A. D. 473–478
 Humphries, S. E. 435–441, 467–472
 Hyun, Y. J. 349–356
- I**hlen, H. 287–296
 Ijzerman, R. G. 83–91
- J**ang, Y. 349–356
 Jansson, T. 1–13
 Jeron, A. 213–218
- K**abitz, H.-J. 243–249
 Kadar, K. 41–46
 Kamper, A. M. 369–374
 Kao, S. J. 279–285
 Kapoor, S. 141–148
 Karemaker, J. M. 329–337
 Karrasch, M. 205–212
 Katovich, M. J. 357–364
 Kim, J. Y. 349–356
- Kim, Y.-S. 401–407
 Kingsbury, M. 473–478
 Ko, M. J. 349–356
 Koh, S. J. 349–356
 Kollai, M. 41–46
 Kotsopoulos, D. 383–391
 Krediet, C. T. P. 401–407
 Krum, H. 119–127
- L**angille, B. L. 15–23
 La Rovere, M. T. 131–140
 Laszlo, A. 41–46
 Lee, J. H. 349–356
 Lemarechal, H. 149–155
 Li, X. C. 183–193
 Limongelli, G. 259–266
 Linzer, M. 401–407
 Lockhart, C. J. 157–170
 Lopes, M. M. 195–204
 López-Farré, A. J. 319–327
 Lubel, J. S. 109–118
 Lunde, K. 287–296
- M**acaya, C. 319–327
 Maestri, R. 131–140
 Magalhães, J. 459–466
 Malan, E. 383–391
 Marchant, J. S. 93–102
 Marenghini, G. 443–448
 Maresch, C. M. 251–258
 Marney, A. M. 267–278
 Marques, F. 459–466
 Martin, J. H. 119–127
 Martín Sánchez, J. 319–327
 Martins de Lima, T. 65–77
 Mateos-Cáceres, P. J. 319–327
 McCaughan, G. W. 109–118
 McFadden, C. B. 141–148
 McGoldrick, R. B. 473–478
 McGrath, B. P. 383–391
 McVeigh, G. E. 157–170
 Medow, M. S. 449–457
 Mehta, R. L. 25–32
 Mersich, B. 41–46
 Meszaros, J. G. 357–364

- Miller, G. J. 467–472
Mori, T. A. 409–416
Muthumala, A. 467–472
- N**
Nasrallah, R. 297–311
Neil, A. H. W. 435–441
Neuparth, M. J. 459–466
Neureuther, K. 213–218
Nyirenda, M. J. 219–232
Nyström, T. 79–81
- O**
O’Connell, A. 251–258
Oliveira, P. J. 459–466
Ordovas, J. M. 349–356
Ortega, A. 319–327
- P**
Pacileo, G. 259–266
Palmen, J. 467–472
Papagna, R. 103–108
Paterna, S. 443–448
Pellerin, D. 25–32
Pérez de Prada, M^a T.
319–327
Pescatello, L. S. 251–258
Peverill, R. E. 383–391
Pévet, P. 417–425
Pinna, G. D. 131–140
Pinter, A. 41–46
Polizzi, G. 443–448
Polonski, L. 205–212
Ponikowski, P. 205–212
Portioli Silva, E. P. 65–77
Powell, T. L. 1–13
Prescott, S. L. 409–416
Procopio, J. 65–77
- Q**
Querci, F. 103–108
Quinn, C. E. 157–170
- R**
Raczak, G. 131–140
Raizada, M. K. 357–364
Ramos Mozo, P. 319–327
Rea, A. 259–266
Rhein, S. 205–212
Ribeiro, G. C. A. 195–204
Riksen, N. P. 33–40
Rim, S. -J. 349–356
Riva, C. 103–108
Rohrbach, M. 205–212
Rongen, G. A. 33–40
Rooyackers, O. 313–318
- S**
Said, H. M. 93–102
Sandercock, G. 129–130
Santiago, J. L. 319–327
Santoro, G. 259–266
Scalzo, S. 443–448
Scartezini, M. 435–441
Schmidt, T. S. 47–63
Schunkert, H. 213–218
Schuster-Klein, C. 417–425
Sedlacek, K. 213–218
Serné, E. H. 83–91
Sharma, R. 25–32
Sheridan, D. J. 473–478
Shin, H. -J. 349–356
Simberg, C. L. 397–399
Sinitskaya, N. 417–425
Smith, C. C. T. 427–434
Smith, H.-J. 287–296
- S**
Smits, P. 33–40
Smolich, J. J. 383–391
Sniderman, A. 365–367
Song, Z.-Z. 393
Stanyer, L. 427–434
Stark, K. 213–218
Stehouwer, C. D. A. 83–91
Stella, A. 103–108
Stephens, J. W. 467–472
Stewart, Jillian M. 357–364
Stewart, Julian M. 449–457
Streater, C. P. 25–32
Subramanian, V. S. 93–102
Szwoch, M. 131–140
- T**
Tack, C. J. 33–40
Taneja, I. 449–457
Tang, J. I. 219–232
Teede, H. J. 383–391
Teixeira, V. P. A. 195–204
Thijs, R. D. 369–374
Thompson, P. D. 251–258
Tornatore, T. F. 195–204
Torunski, A. 131–140
Townsend, R. R. 141–148
Tsongalis, G. J. 251–258
Turner, M. A. 473–478
- V**
Valsecchi, M. G. 103–108
van der Kallen, C. J. H.
375–381
van Dijk, A. D. 369–374
van Dijk, J. G. 369–374
- van Greevenbroek, M. M. J.
375–381
Van Lieshout, J. J. 401–407
van Lin, J. M. J. P. 375–381
van Weissenbruch, M. M.
83–91
Vartdal, T. 287–296
Verheyden, B. 329–337
Vermeulen, V. M. M.-J.
375–381
Verrengia, M. 259–266
Villaruel, P. 319–327
Vitale, G. 443–448
Voordouw, J. J. 83–91
- W**
Walker, D. 243–249
Walterspacher, S. 243–249
Wark, J. D. 233–241
Warner, F. J. 109–118
Weidenhielm, L. 313–318
Wernerman, J. 313–318
Wesseling, K. H. 329–337
Westman, B. 313–318
Whittall, R. A. 435–441
Wiedmann, S. 213–218
Wieling, W. 329–337,
401–407
Windisch, W. 243–249
Wong, P. K. K. 233–241
- Y**
Yeh, D. Y.-W. 279–285
- Z**
Zerbini, G. 103–108
Zhuo, J. L. 183–193

S U B J E C T I N D E X

- A**cute coronary syndrome
end-stage renal disease, myocardial ischaemia 25–32
- Acute myocardial infarction
parathyroid-hormone-related protein (PTHrP), platelet activation 319–327
- Acute pericarditis
non-steroidal anti-inflammatory drug (NSAID), statin 443–448
- Acute respiratory distress syndrome (ARDS)
fat embolism, pro-inflammatory cytokine 279–285
- α -Adducin
exercise, hypertension 251–258
- Adiposity
coagulation, fibrinolysis 383–391
- Age
tilt testing, vasovagal response 329–337
- Aldosterone
end-organ damage, mineralocorticoid receptor 267–278
- β -Amyloid
low-density lipoprotein (LDL), vasoactive action 427–434
- Angiotensin II (AngII)
body mass index (BMI), postural tachycardia syndrome (POTS) 449–457
liver, renin–angiotensin system 109–118
- Angiotensin-converting enzyme (ACE)
cardiac fibroblast, hypoxia 357–364
obesity, Type 2 diabetes 467–472
- Aortic banding
left ventricular hypertrophy, vasodilation 473–478
- Aortic coarctation
myocardial abnormality, ventricular function 259–266
- Arterial mechanics
arterial stiffness, cardiovascular risk 157–170
- Arterial remodelling
haemodynamic function, vascular tone 15–23
- Arterial stiffness
arterial mechanics, cardiovascular risk 157–170
- Atherosclerosis
endothelial function, nitric oxide synthase 47–63
- Autonomic nervous system
orthostasis, strain gauge plethysmography 369–374
- B**aroreflex sensitivity
carotid artery stiffness, transposition of great arteries (TGA) 41–46
- Body mass index (BMI)
angiotensin II (AngII), postural tachycardia syndrome (POTS) 449–457
- Bone health
osteoporosis, smoking 233–241
- C**apillary recruitment
glucocorticoid, hypertension 83–91
- Cardiac fibroblast
angiotensin-converting enzyme (ACE), hypoxia 357–364
- Cardiovascular risk
arterial stiffness, arterial mechanics 157–170
hip circumference, postmenopausal woman 383–391
lipoprotein, protein convertase subtilisin/kexin 9 gene (PCSK9) 435–441
- Carnitine palmitoyltransferase I
congestive heart failure, energy metabolism 205–212
- Carotid artery stiffness
baroreflex sensitivity, transposition of great arteries (TGA) 41–46
- Cellular targeting
human thiamine transporter (hTHTR), micronutrient 93–102
- Chronic obstructive pulmonary disease (COPD)
inspiratory muscle strength, twitch mouth pressure 243–249
- Coagulation
adiposity, fibrinolysis 383–391
- Complement factor H gene (CFH)
myocardial infarction, polymorphism 213–218
- Congestive heart failure
carnitine palmitoyltransferase I, energy metabolism 205–212
- Coronary artery disease
gene polymorphism, RANTES 349–356
- C-reactive protein (CRP)
insulin resistance, Type 2 diabetes 79–81, 103–108
- Cyclo-oxygenase (COX)
kidney, prostaglandin 297–311
- E**CG
heart rate variability, RR interval 128–130, 131–140
- End-organ damage
aldosterone, mineralocorticoid receptor 267–278
- Endothelial function
atherosclerosis, nitric oxide synthase 47–63
- End-stage renal disease
acute coronary syndrome, myocardial ischaemia 25–32
- Energy homeostasis
melanocortin, pro-opiomelanocortin (POMC) 171–182
- Energy metabolism
carnitine palmitoyltransferase I, congestive heart failure 205–212
- Exercise
 α -adducin, hypertension 251–258

- F**
Familial combined hyperlipidaemia (FCHL)
 lipid phenotype, liver 365–367, 375–381
Fat embolism
 acute respiratory distress syndrome (ARDS), pro-inflammatory cytokine 279–285
Fat-to-carbohydrate ratio
 high-fat diet, obesity 397–399, 417–425
Fatty acid
 inflammation, leucocyte 65–77
Fetal programming
 glucocorticoid, 11β -hydroxysteroid dehydrogenase (11β -HSD) 219–232
 nutrition, placental transport 1–13
Fibrinolysis
 adiposity, coagulation 383–391
Fish oil
 neonatal immune response, pregnancy 409–416
Focal adhesion kinase
 heart failure, volume overload 195–204
- G**
Gene polymorphism
 coronary artery disease, RANTES 349–356
Glucagon
 metabolic syndrome, Type 2 diabetes 183–193
Glucocorticoid
 capillary recruitment, hypertension 83–91
 fetal programming, 11β -hydroxysteroid dehydrogenase (11β -HSD) 219–232
- H**
Haemodynamic function
 arterial remodelling, vascular tone 15–23
Heart failure
 focal adhesion kinase, volume overload 195–204
 myocardial infarction, statin 119–127
Heart rate variability
 ECG, RR interval 128–130, 131–140
High altitude
 skeletal muscle, vitamin E 459–466
- H**
High-fat diet
 fat-to-carbohydrate ratio, obesity 397–399, 417–425
Human thiamine transporter (hTHTR)
 cellular targeting, micronutrient 93–102
 11β -Hydroxysteroid dehydrogenase (11β -HSD)
 fetal programming, glucocorticoid 219–232
Hypertension
 α -adducin, exercise 251–258
 capillary recruitment, glucocorticoid 83–91
Hypobaric hypoxia
 mitochondrial dysfunction, vitamin E 459–466
Hypoxia
 angiotensin-converting enzyme (ACE), cardiac fibroblast 357–364
- I**
Inflammation
 fatty acid, leucocyte 65–77
Inflammatory state
 angiotensin-converting enzyme (ACE), gene–environment interaction 467–472
Initial orthostatic hypotension (IOH)
 muscle tensing, posture 401–407
Inspiratory muscle strength
 chronic obstructive pulmonary disease (COPD), twitch mouth pressure 243–249
Insulin resistance
 C-reactive protein (CRP), Type 2 diabetes 79–81, 103–108
Insulin sensitivity
 salt intake, sympathetic nervous system 141–148
Ischaemia/reperfusion
 knee replacement surgery, skeletal muscle 313–318
- K**
Kidney
 cyclo-oxygenase (COX), prostaglandin 297–311
Knee replacement surgery
 ischaemia/reperfusion, skeletal muscle 313–318
- L**
Left ventricular hypertrophy
 aortic banding, vasodilation 473–478
Leucocyte
 fatty acid, inflammation 65–77
- L**
Leukotriene
 $n-3$ fatty acid, pregnancy 409–416
Lipid phenotype
 familial combined hyperlipidaemia (FCHL), liver 365–367, 375–381
Lipoprotein
 cardiovascular risk, protein convertase subtilisin/kexin 9 gene (PCSK9) 435–441
Liver
 angiotensin II (AngII), renin–angiotensin system 109–118
 familial combined hyperlipidaemia (FCHL), lipid phenotype 365–367, 375–381
Longitudinal strain
 myocardial infarction, two-dimensional speckle tracking echocardiography 287–296, 393, 394–395
Low-density lipoprotein (LDL)
 β -amyloid, vasoactive action 427–434
- M**
Melanocortin
 energy homeostasis, pro-opiomelanocortin (POMC) 171–182
Mesenchymal stem cell
 regenerative medicine, rheumatology 339–348
Metabolic syndrome
 glucagon, Type 2 diabetes 183–193
Micronutrient
 cellular targeting, human thiamine transporter (hTHTR) 93–102
Mineralocorticoid receptor
 aldosterone, end-organ damage 267–278
Mitochondrial dysfunction
 hypobaric hypoxia, vitamin E 459–466
Muscle tensing
 initial orthostatic hypotension (IOH), posture 401–407
Myocardial abnormality
 aortic coarctation, ventricular function 259–266
Myocardial infarction
 complement factor H gene (CFH), polymorphism 213–218
 heart failure, statin 119–127

- longitudinal strain, two-dimensional speckle tracking
 echocardiography 287–296, 393, 394–395
- Myocardial ischaemia
 acute coronary syndrome, end-stage renal disease 25–32
- N**eonatal immune response
 fish oil, pregnancy 409–416
- Nitric oxide synthase
 atherosclerosis, endothelial function 47–63
- Non-esterified fatty acid
 pulse wave velocity, vasodilation 33–40
- Non-steroidal anti-inflammatory drug (NSAID)
 acute pericarditis, statin 443–448
- Nutrition
 fetal programming, placental transport 1–13
- O**besity
 angiotensin-converting enzyme (ACE), Type 2 diabetes 467–472
 fat-to-carbohydrate ratio, high-fat diet 397–399, 417–425
- Orthostasis
 autonomic nervous system, strain gauge plethysmography 369–374
- Osteoporosis
 bone health, smoking 233–241
- P**arathyroid-hormone-related protein (PTHrP)
 platelet activation, acute myocardial infarction 319–327
- Placental transport
 fetal programming, nutrition 1–13
- Platelet activation
 acute myocardial infarction, parathyroid-hormone-related protein (PTHrP) 319–327
- Polymorphism
 complement factor H gene (*CFH*), myocardial infarction 213–218
- Postural tachycardia syndrome (POTS)
 angiotensin II (AngII), body mass index (BMI) 449–457
- Posture
 initial orthostatic hypotension (IOH), muscle tensing 401–407
- Pregnancy
 fish oil, neonatal immune response 409–416
- Pro-inflammatory cytokine
 acute respiratory distress syndrome (ARDS), fat embolism 279–285
 rheumatoid arthritis, synoviocyte 149–155
- Pro-opiomelanocortin (POMC)
 energy homeostasis, melanocortin 171–182
- Prostaglandin
 cyclo-oxygenase (COX), kidney 297–311
- Protein convertase subtilisin/kexin 9 gene (*PCSK9*)
 cardiovascular risk, lipoprotein 435–441
- Pulse wave velocity
 non-esterified fatty acid, vasodilation 33–40
- R**ANTES (regulated upon activation normal T-cell expressed and secreted)
 coronary artery disease, gene polymorphism 349–356
- Regenerative medicine
 mesenchymal stem cell, rheumatology 339–348
- Renin–angiotensin system
 angiotensin II (AngII), liver 109–118
- Rheumatoid arthritis
 pro-inflammatory cytokine, synoviocyte 149–155
- Rheumatology
 mesenchymal stem cell, regenerative medicine 339–348
- RR interval
 ECG, heart rate variability 128–130, 131–140
- S**alt intake
 insulin sensitivity, sympathetic nervous system 141–148
- Skeletal muscle
 ischaemia/reperfusion, knee replacement surgery 313–318
- Smoking
 bone health, osteoporosis 233–241
- Statin
 acute pericarditis, non-steroidal anti-inflammatory drug (NSAID) 443–448
 heart failure, myocardial infarction 119–127
- Strain gauge plethysmography
 autonomic nervous system, orthostasis 369–374
- Sympathetic nervous system
 insulin sensitivity, salt intake 141–148
- Synoviocyte
 pro-inflammatory cytokine, rheumatoid arthritis 149–155
- T**ilt testing
 age, vasovagal response 329–337
- Transposition of great arteries (TGA)
 baroreflex sensitivity, carotid artery stiffness 41–46
- Twitch mouth pressure
 chronic obstructive pulmonary disease (COPD), inspiratory muscle strength 243–249
- Two-dimensional speckle tracking
 echocardiography
 longitudinal strain, myocardial infarction 287–296, 393, 394–395
- Type 2 diabetes
 angiotensin-converting enzyme (ACE), obesity 467–472
 C-reactive protein (CRP), insulin resistance 79–81, 103–108
 glucagon, metabolic syndrome 183–193
 high-fat diet, prediabetic state 397–399, 417–425
- V**ascular tone
 arterial remodelling, haemodynamic function 15–23
- Vasoactive action
 β -amyloid, low-density lipoprotein (LDL) 427–434
- Vasodilation
 aortic banding, left ventricular hypertrophy 473–478
 non-esterified fatty acid, pulse wave velocity 33–40
- Vasovagal response
 age, tilt testing 329–337
- Ventricular function
 aortic coarctation, myocardial abnormality 259–266
- Vitamin E
 hypobaric hypoxia, mitochondrial dysfunction 459–466
- Volume overload
 focal adhesion kinase, heart failure 195–204